Research

Ecallantide for Patients with Angioedema

Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks

Protocol Description

This study tests a medication called ecallantide, also known as DX-88, for treatment of angioedema attacks. Angioedema is a rare inherited illness, in which the patient gets attacks of swelling in the face, arms, legs, and abdomen and/or in the area of the throat. These attacks are unpleasant, may be painful, and if breathing difficulties occur, may be life threatening. Although steroids or drugs influencing blood clotting can be used as preventive medication, their use cannot completely prevent angioedema attacks and may also associated with negative side effects. DX-88 works differently in the blood and may prove to be a better approach.

Eligibility Criteria

Males and females, ages 10 and up, who have been diagnosed with hereditary angioedema may be eligible to participate. Participants in an existing DX-88/20 study may also be eligible.
Males: Age 10 and up
Females: Age 10 and up

Requirements
Following screening procedures, patients selected for the study will receive physical exams during follow-up visits. The study medication will be administered following onset of their next angioedema attack, and their condition will then be monitored at specific intervals as prescribed by the study protocol for about three months.
Visits: Up to 7
Duration: Varies depending on when patients experience an angioedema attack

Status: Open for Enrollment

Source of Support
Dyax Corp.

Additional Resources
Study description at National Institutes of Health